Antitumor IgE adjuvanticity

Key role of FcεRI

Elisa A. Nigro, Anna T. Brini, Elisa Soprana, Alessandro Ambrosi, David Dombrowicz, Antonio G. Siccardi, Luca Vangelista

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Working with C57BL/6 mouse tumor models, we had previously demonstrated that vaccination with IgE-coated tumor cells can protect against tumor challenge, an observation that supports the involvement of IgE in antitumor immunity. The adjuvant effect of IgE was shown to result from eosinophil-dependent priming of the T cell-mediated adaptive immune response. The protective effect is likely to be mediated by the interaction of tumor cell-bound IgE with receptors, which then trigger the release of mediators, recruitment of effector cells, cell killing and tumor Ag cross-priming. It was therefore of utmost importance to demonstrate the strict dependence of the protective effect on IgE receptor activation. First, the protective effect of IgE was confirmed in a BALB/c tumor model, in which IgE-loaded modified VV Ankara-infected tumor cells proved to be an effective cellular vaccine. However, the protective effect was lost in FcεRIα-/- (but not in CD23-/-) knockout mice, showing the IgE-FcεRI interaction to be essential. Moreover, human IgE (not effective in BALB/c mice) had a protective effect in the humanized knockin mouse (FcεRIα-/- hFcεRIα+). This finding suggests that the adjuvant effect of IgE could be exploited for human therapeutics.

Original languageEnglish
Pages (from-to)4530-4536
Number of pages7
JournalJournal of Immunology
Volume183
Issue number7
DOIs
Publication statusPublished - Oct 1 2009
Externally publishedYes

Fingerprint

Immunoglobulin E
Neoplasms
IgE Receptors
Cross-Priming
Adaptive Immunity
Inbred C57BL Mouse
Eosinophils
Knockout Mice
Cell Communication
Immunity
Vaccination
Vaccines
Observation
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Nigro, E. A., Brini, A. T., Soprana, E., Ambrosi, A., Dombrowicz, D., Siccardi, A. G., & Vangelista, L. (2009). Antitumor IgE adjuvanticity: Key role of FcεRI. Journal of Immunology, 183(7), 4530-4536. https://doi.org/10.4049/jimmunol.0900842

Antitumor IgE adjuvanticity : Key role of FcεRI. / Nigro, Elisa A.; Brini, Anna T.; Soprana, Elisa; Ambrosi, Alessandro; Dombrowicz, David; Siccardi, Antonio G.; Vangelista, Luca.

In: Journal of Immunology, Vol. 183, No. 7, 01.10.2009, p. 4530-4536.

Research output: Contribution to journalArticle

Nigro, EA, Brini, AT, Soprana, E, Ambrosi, A, Dombrowicz, D, Siccardi, AG & Vangelista, L 2009, 'Antitumor IgE adjuvanticity: Key role of FcεRI', Journal of Immunology, vol. 183, no. 7, pp. 4530-4536. https://doi.org/10.4049/jimmunol.0900842
Nigro EA, Brini AT, Soprana E, Ambrosi A, Dombrowicz D, Siccardi AG et al. Antitumor IgE adjuvanticity: Key role of FcεRI. Journal of Immunology. 2009 Oct 1;183(7):4530-4536. https://doi.org/10.4049/jimmunol.0900842
Nigro, Elisa A. ; Brini, Anna T. ; Soprana, Elisa ; Ambrosi, Alessandro ; Dombrowicz, David ; Siccardi, Antonio G. ; Vangelista, Luca. / Antitumor IgE adjuvanticity : Key role of FcεRI. In: Journal of Immunology. 2009 ; Vol. 183, No. 7. pp. 4530-4536.
@article{080d3990cc82476ab83ca464ac75efa8,
title = "Antitumor IgE adjuvanticity: Key role of FcεRI",
abstract = "Working with C57BL/6 mouse tumor models, we had previously demonstrated that vaccination with IgE-coated tumor cells can protect against tumor challenge, an observation that supports the involvement of IgE in antitumor immunity. The adjuvant effect of IgE was shown to result from eosinophil-dependent priming of the T cell-mediated adaptive immune response. The protective effect is likely to be mediated by the interaction of tumor cell-bound IgE with receptors, which then trigger the release of mediators, recruitment of effector cells, cell killing and tumor Ag cross-priming. It was therefore of utmost importance to demonstrate the strict dependence of the protective effect on IgE receptor activation. First, the protective effect of IgE was confirmed in a BALB/c tumor model, in which IgE-loaded modified VV Ankara-infected tumor cells proved to be an effective cellular vaccine. However, the protective effect was lost in FcεRIα-/- (but not in CD23-/-) knockout mice, showing the IgE-FcεRI interaction to be essential. Moreover, human IgE (not effective in BALB/c mice) had a protective effect in the humanized knockin mouse (FcεRIα-/- hFcεRIα+). This finding suggests that the adjuvant effect of IgE could be exploited for human therapeutics.",
author = "Nigro, {Elisa A.} and Brini, {Anna T.} and Elisa Soprana and Alessandro Ambrosi and David Dombrowicz and Siccardi, {Antonio G.} and Luca Vangelista",
year = "2009",
month = "10",
day = "1",
doi = "10.4049/jimmunol.0900842",
language = "English",
volume = "183",
pages = "4530--4536",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "7",

}

TY - JOUR

T1 - Antitumor IgE adjuvanticity

T2 - Key role of FcεRI

AU - Nigro, Elisa A.

AU - Brini, Anna T.

AU - Soprana, Elisa

AU - Ambrosi, Alessandro

AU - Dombrowicz, David

AU - Siccardi, Antonio G.

AU - Vangelista, Luca

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Working with C57BL/6 mouse tumor models, we had previously demonstrated that vaccination with IgE-coated tumor cells can protect against tumor challenge, an observation that supports the involvement of IgE in antitumor immunity. The adjuvant effect of IgE was shown to result from eosinophil-dependent priming of the T cell-mediated adaptive immune response. The protective effect is likely to be mediated by the interaction of tumor cell-bound IgE with receptors, which then trigger the release of mediators, recruitment of effector cells, cell killing and tumor Ag cross-priming. It was therefore of utmost importance to demonstrate the strict dependence of the protective effect on IgE receptor activation. First, the protective effect of IgE was confirmed in a BALB/c tumor model, in which IgE-loaded modified VV Ankara-infected tumor cells proved to be an effective cellular vaccine. However, the protective effect was lost in FcεRIα-/- (but not in CD23-/-) knockout mice, showing the IgE-FcεRI interaction to be essential. Moreover, human IgE (not effective in BALB/c mice) had a protective effect in the humanized knockin mouse (FcεRIα-/- hFcεRIα+). This finding suggests that the adjuvant effect of IgE could be exploited for human therapeutics.

AB - Working with C57BL/6 mouse tumor models, we had previously demonstrated that vaccination with IgE-coated tumor cells can protect against tumor challenge, an observation that supports the involvement of IgE in antitumor immunity. The adjuvant effect of IgE was shown to result from eosinophil-dependent priming of the T cell-mediated adaptive immune response. The protective effect is likely to be mediated by the interaction of tumor cell-bound IgE with receptors, which then trigger the release of mediators, recruitment of effector cells, cell killing and tumor Ag cross-priming. It was therefore of utmost importance to demonstrate the strict dependence of the protective effect on IgE receptor activation. First, the protective effect of IgE was confirmed in a BALB/c tumor model, in which IgE-loaded modified VV Ankara-infected tumor cells proved to be an effective cellular vaccine. However, the protective effect was lost in FcεRIα-/- (but not in CD23-/-) knockout mice, showing the IgE-FcεRI interaction to be essential. Moreover, human IgE (not effective in BALB/c mice) had a protective effect in the humanized knockin mouse (FcεRIα-/- hFcεRIα+). This finding suggests that the adjuvant effect of IgE could be exploited for human therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=70449732758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449732758&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0900842

DO - 10.4049/jimmunol.0900842

M3 - Article

VL - 183

SP - 4530

EP - 4536

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 7

ER -